News Releases

News & Events

News Releases

Synteract Continues Its Conference and Speaking Engagements in November

SAN DIEGO – Nov. 10, 2016 – Executives from Synteract, a full-service, international contract research organization (CRO), are continuing to exhibit and speak at various industry conferences around the globe in November. The events include World Immunotherapy Congress, World Orphan Drug Congress Europe and Partnerships in Clinical Trials Europe. Each event brings together thought leaders from biotech, pharma and related industries to network and stay abreast of new developments and best practices.

The World Immunotherapy Congress, Nov. 14-16 at Congress Center in Basel, Switzerland, offers experts multiple opportunities to discuss the promising developments in immunotherapy, including immune checkpoint inhibitors and cell therapy. Synteract will exhibit in booth #28 and will have clinical trial experts available to meet with companies that are focused on developing oncology and other therapeutic indication trials using immunotherapy techniques. To make an appointment to meet with Synteract, contact Volker Knorz:

The World Orphan Drug Congress Europe 2016 will be held Nov. 15-17 in Brussels, where Dr. Stephan de la Motte, chief medical advisor for Synteract, will host two roundtables: the first on “Sharing Practical Insights on the Planning and Execution of Orphan Drug Clinical Trials” at 11:30 am on Wed., Nov. 16th and the second on the same topic (time, date). Clients and others who might like to meet with the team at World Orphan may contact Alexandre Wallard:  

At the Partnerships in Clinical Trials Europe (PCT) event, Vice President for Global Medical and Regulatory Affairs Dr. Martine Dehlinger-Kremer will present: “Planning for the Impact of the New EU Clinical Trials Regulation and the Implications of the UK Brexit” from 11:25 a.m. – 12:00 p.m. EDT on Thursday, November 17th. Attendees will leave the presentation prepared for the upcoming EU Regulation and will better understand how Brexit may affect the new regulation. Synteract will exhibit in booth #173.

Lastly, clinical trial experts from the company will also attend BVMA in Munich from Nov. 24-25th, 2016. Those who wish to meet with the team at either PCT or BVMA, or with Dr. Dehlinger-Kremer, may contact Xavier Morillon:

See Synteract's full schedule of events and follow its social channels on LinkedIn and Twitter for live updates during all conferences.

About Synteract
Synteract is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. Synteract has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, Synteract provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.

# # #
Beth Walsh


Contact Synteract

Tell us how to stay in touch with you: